News


Corium Prices Follow-On Offering of Common Stock

Thursday , 25 May 2017

 

MENLO PARK, Calif., May 25, 2017 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the pricing of its underwritte...

READ MORE...


Earth Science Tech, Inc. Presents at SeeThruEquity Microcap Investor’s 6th Annual Conference in Ne

Thursday , 25 May 2017

 

Hollywood, May 25, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCPINK: ETST), an innovative biotech company focused on cannabis CBD-based (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, medical devices and its subsidiary, Cannabis Therapeutics Inc., will attend and present at SeeThruEquity Microcap Investor...

READ MORE...


EnglishFrançais Search Register Sign In Intra-Cellular Therapies to Present at the American Soci

Thursday , 25 May 2017

 

NEW YORK, May 25, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced it will present four presentations at the American Society of C...

READ MORE...


Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics

Thursday , 25 May 2017

 

Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics

Funding to advance two of Harpoon's immuno-oncology programmes into clinical trials -

LONDON, 25 May, 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science company supporting medical innovation, today announced that Harpoon Therapeutics, a new Arix Group Business, has closed a Series B investment r...

READ MORE...


Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics

Thursday , 25 May 2017

 

Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics

Funding to advance two of Harpoon's immuno-oncology programmes into clinical trials -

LONDON, 25 May, 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science company supporting medical innovation, today announced that Harpoon Therapeutics, a new Arix Group Business, has closed a Series B investment r...

READ MORE...


Advanced Accelerator Applications Appoints Christine Mikail to Board of Director

Thursday , 25 May 2017

 

SAINT-GENIS-POUILLY, France, May 25, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced that Christin...

READ MORE...


Elite Pharmaceuticals’ SequestOx™ Study Results Expected in July

Thursday , 25 May 2017

 

NORTHVALE, N.J., May 25, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), today announced that top-line results for its reformulated SequestOx™ study are expected in July 2017. Patient disqualificatio...

READ MORE...


Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues at World Advanced Ther

Thursday , 18 May 2017

 

SAN DIEGO, May 18, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today presented new preclinical data showing exten...

READ MORE...


Recro Pharma Presents Phase III Bunionectomy Clinical Data for IV Meloxicam at the American Pain S

Thursday , 18 May 2017

  

Recro Pharma Presents Phase III Bunionectomy Clinical Data for IV Meloxicam at the American Pain Society 36th Annual Scientific Meeting

Poster Presentation Highlighting Clinical Performance of IV Meloxicam 30mg, Including Statistically Significant Differences in SPID48 and Numerous Other Rescue Use and Pain Reli...

READ MORE...


XOMA Earns $10 Million Milestone Payment as Another of its Licensed Assets Advances into Clinical

Thursday , 18 May 2017

 

BERKELEY, Calif., May 18, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, today announced it has earned a $10 million milestone payment, reflecting the clinical advancement of an asset the Company license...

READ MORE...


Featured Employers

© 2017 Jobsinpharma - 4ward Technologies Ltd All rights reserved.